Status:
COMPLETED
Hip Fracture Study of GSK576428 (Fondaparinux Sodium)
Lead Sponsor:
GlaxoSmithKline
Conditions:
Thromboembolism
Eligibility:
All Genders
20+ years
Phase:
PHASE3
Brief Summary
This study is requested by PMDA to confirm the efficacy and the safety for HFS.
Eligibility Criteria
Inclusion
- Patients undergoing hip fracture surgery within 10 days following the time of fracture of the hip (proximal femur) (or following the time of fracture estimated from trauma).
Exclusion
- Active, clinically significant bleeding (excluding drainage).
Key Trial Info
Start Date :
February 16 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 26 2006
Estimated Enrollment :
48 Patients enrolled
Trial Details
Trial ID
NCT00320424
Start Date
February 16 2006
End Date
October 26 2006
Last Update
September 4 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site